Full-Time

Machine Learning Engineer

AI Platform

Posted on 1/27/2026

ArteraAI

ArteraAI

51-200 employees

Delivers CLIA-certified multi-modal prostate cancer test

Compensation Overview

$140k - $180k/yr

No H1B Sponsorship

Remote in USA

Remote

Category
AI & Machine Learning (1)
Required Skills
Kubernetes
Python
Tensorflow
Pytorch
MLflow
Docker
AWS
Requirements
  • 4+ years of industry software engineering experience
  • 2+ years of industry experience in using ML orchestration frameworks such as Flyte, Ray, Kubeflow, Metaflow, MLFlow, Dagster, Argo Workflow or Prefect
  • 2+ years of industry experience using one of PyTorch, TensorFlow, or JAX in Python
  • 2+ years of industry experience building with AWS, Docker, and Kubernetes
  • 1+ years of industry experience optimizing large-scale, high data-throughput, distributed machine learning training pipelines
Responsibilities
  • Build and evolve the core libraries used by AI scientists to develop, launch, and monitor AI products.
  • Help manage Artera’s ML compute infrastructure including scaling up Artera’s Foundation Model development by developing distributed training infrastructure and developer libraries.
  • Work with model developers to optimize GPU and CPU efficiency and data throughput of large-scale foundation models and downstream model training runs.
  • Optimize Artera’s ability to store and process terabytes of digital pathology data efficiently for the use in serving large-scale training regimes.
  • Ensure that Artera’s observability infrastructure provides a clear picture of how to continue to optimize performance across our model landscape.
Desired Qualifications
  • Experience using Terraform, SqlAlchemy
  • Experience in multi-node and multi-gpu training.
  • Experience deploying and maintaining infrastructure for machine learning training and production inference
  • Familiarity with TorchScript, ONNXRuntime, DeepSpeed, AWS Neuron or similar approaches to inference optimization

ArteraAI develops personalized prostate cancer therapy solutions using multi-modal deep learning. Its flagship offering, the ArteraAI Prostate Test, is a high-complexity CLIA-certified clinical laboratory test performed in-house and used in clinical care. The test analyzes diverse data through advanced AI to tailor treatment decisions for individual patients. Unlike many competitors, ArteraAI integrates randomized phase III trial-informed science, in-house product development, and routine publications to support credibility, and targets a shift toward personalized, data-driven prostate cancer therapies. The company's goal is to equip healthcare providers with reliable, data-backed tools to personalize treatment plans, improving outcomes for patients while expanding adoption across hospitals, clinics, and other care settings.

Company Size

51-200

Company Stage

Early VC

Total Funding

$175M

Headquarters

Menlo Park, California

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus partnership accesses 50% of US oncologists, driving ArteraAI Prostate test adoption.
  • FDA clearance for ArteraAI Breast in 2026 validates MMAI platform expansion beyond prostate.
  • $65M investment and $100M CARR milestone signal strong commercial traction.

What critics are saying

  • Tempus exclusivity enables pricing pressure and volume diversion to its AI tools within 12 months.
  • Paige.AI's FDA-cleared prostate AI steals pathology lab contracts from Artera in 6 months.
  • Decipher and Oncotype DX dominate NCCN guidelines, undercutting Artera reimbursement in 12 months.

What makes ArteraAI unique

  • ArteraAI Prostate Test uniquely predicts hormone therapy benefit and prognosticates outcomes using MMAI on biopsy images.
  • First AI test included in 2024 NCCN Guidelines with Level IB evidence from Phase 3 trials.
  • FDA Breakthrough Designation for ArteraAI Prostate on July 9, 2025, accelerates approval.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Urology Times
Jan 4th, 2026
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions

Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions. Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. On December 9, 2025, Artera announced the commercial launch of the ArteraAI Prostate Test (Post-RP), a tool designed to help identify which patients with biochemical recurrence following radical prostatectomy may benefit from intensified salvage therapy.[1] Specifically, the multimodal artificial intelligence (MMAI) test provides prognostic insight into the potential benefit of adding short-term androgen deprivation therapy (ADT) to radiation. In an interview with Urology Times(R), Daniel Spratt, MD, a radiation oncologist at University Hospitals Seidman Cancer Center in Cleveland, Ohio, discussed the clinical challenges of managing biochemical recurrence and how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. According to Spratt, clinicians have long lacked a reliable tool to support decision-making in this setting - a gap the ArteraAI Prostate Test was developed to address. Spratt explained, "This [test] uses [patients'] clinical and pathologic features as well as, very importantly, digital pathology, running an artificial intelligence algorithm to help us put all these features together to identify patients at low risk of developing recurrence and metastatic disease vs those patients at much higher risk." "When you use this MMAI test, it's really profound. Those with a low MMAI score have a much lower risk of developing recurrence or metastatic disease. So, the benefit of hormone therapy is only a couple percent. It's not zero, but it's a much smaller benefit vs when you find a patient who has a high MMAI score, [where] you're talking about benefits of 20% or higher in terms of reductions in metastatic disease," said Spratt. 1. Artera debuts ArteraAI Prostate Test (Post-RP), expanding its oncology portfolio. News release. Artera. December 9, 2025. Accessed January 1, 2025. 2. New data validating the first AI-based biomarker to stratify risk of metastasis in radical prostatectomy patients with biochemical recurrence. News release. Artera. May 6, 2024. Accessed January 1, 2025. Stay current with the latest urology news and practice-changing insights - sign up now for the essential updates every urologist needs.

Artera
Dec 5th, 2025
Artera Secures $65M Growth Investment and Reaches $100M CARR - Artera

Artera announces a $65M growth investment and a major milestone of reaching $100 million in Contracted Annual Recurring Revenue (CARR)..

ITN Online
Sep 29th, 2025
Artera Unveils Four Presentations at ASTRO 2025 Addressing Personalized Cancer Care

Sept. 26, 2025 - Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present four abstracts at the 2025 American Society for Radiation Oncology Annual Meeting (ASTRO) in San Francisco, Calif..

Business Wire
May 30th, 2025
Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care

Artera presenting validation data at 2025 ASCO Annual Meeting highlighting how multimodal AI platform (MMAI) is advancing personalized cancer care.

HIT Consultant
May 9th, 2025
Ai Study Challenges Fears Of Racial Bias In Prostate Cancer Care

AI Study Challenges Fears of Racial Bias in Prostate Cancer Care. by Fred Pennic 05/09/2025 Leave a Comment. What You Should Know: – Artera, a company developing multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the publication of a significant validation study in the JCO Clinical Cancer Informatics. – The study rigorously assessed Artera’s MMAI model and confirmed its ability to perform similarly across different racial subgroups using data from diverse prostate cancer clinical trials.Addressing the Challenge of AI Racial Bias in OncologyThis research comes at a crucial time as AI tools are increasingly integrated into clinical decision-making. However, valid concerns persist that these technologies could inadvertently worsen healthcare inequities due to racial bias, particularly if developed using datasets not representative of real-world patient populations. This is a pronounced concern in prostate cancer, where African American men have historically faced a worse prognosis, partly attributed to their underrepresentation in the development of AI tools and genomic biomarkers. Many current AI models have been trained on datasets that lack diversity, raising questions about their applicability and fairness across all patient groups

INACTIVE